Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
This article outlines scenarios where target date funds may be preferable to index funds in a 401(k), focusing on simplicity and risk management.
26,105 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Kaspi.kz faces a pivotal year as it expands its super app, grows its loan book, and navigates regional headwinds. Thi...
Bloom Energy surges in Q4 2025 on AI-driven data-center demand, delivering record revenue and EBITDA. Plug Power turn...
Duolingo stock fell February as investors reeled from a shaky user metric and rising AI disruption concerns. This art...
Santander sinks 12.6% as unconfirmed trade news swirls around US-Spain tensions, but the bank’s 2025 profits and effi...
A new stake in Vista Energy signals rising institutional interest in the energy sector. This article breaks down why ...
As mortgage markets wobble in March 2026, Ninja Selling’s Larry Kendall champions a habit-first approach for loan off...
Oil prices jump and inflation data loom, setting the stage for a volatile week in crypto markets as traders weigh mac...
SharpLink Gaming Stock posted a $734 million full-year loss tied to its Ethereum holdings, signaling a new era of cry...
What to expect from Kodiak’s 2025 earnings? This guide breaks down revenue drivers, margins, and realistic scenarios ...
Florida enters its worst drought in a generation, worsening the squeeze on citrus farmers already dealing with diseas...
AI is reshaping hiring in three AI-driven domains, even as revenue growth decouples from headcount. The shift signals...